Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 3, 2010, Pages 195-199

  Yagasaki, H ^a   Kobayashi, K ^a   Saitou, T ^a   Nagamine, K ^a   Mitsui, Y ^a   Mochizuki, M ^a   Cho, H ^b   Ohyama, K ^a   Amemiya, S ^c   Nakazawa, S ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Dawn phenomenon; Insulin like growth factor binding protein 1; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN GLARGINE; ISOPHANE INSULIN; SOMATOMEDIN BINDING PROTEIN 1;

ADOLESCENT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTINUOUS INFUSION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL;

ADOLESCENT; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN, NPH; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; MALE;

EID: 77949518068     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1239518     Document Type: Article

References (14)

1. Dunger DB, Regan FM, Acerini CL. Childhood and adolescent diabetes. Endocr Dev 2005 9 107-120
2. Frystyk J, Nyholm B, Skjaerbaek C, etal. The circulating IGF system and its relationship with 24h glucose regulation and insulin sensitivity in healthy subjects. Clin Endocrinol 2003 58 777-784
3. Hilding A, Brismar K, Degerblad M, etal. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995 80 2646-2652
4. Kobayashi K, Amemiya S, Sawanobori E, etal. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care 1997 20 1442-1447
5. Lang CH, Vary TC, Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology 2003 144 3922-3933
6. Inokuchi M, Hasegawa T, Anzo M, etal. Standardized centile curves of body mass index for Japanese children and adolescents based on the 19781981 national survey data. Ann Hum Biol 2006 33 444-453
7. Le Floch JP, Lvy M, Mosnier-Pudar H, etal. Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009 32 32-37
8. Lee PD, Giudice LC, Conover CA, etal. Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc Soc Exp Biol Med 1997 216 319-357
9. Perriello G, De Feo P, Torlone E, etal. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 1990 33 52-59
10. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002 25 593-598
11. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008 31 (Suppl 2) S140-S145
12. Rosenstock J, Park G, Zimmerman J, U. S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U. S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000 23 1137-1142
13. Schmidt MI, Hadji-Georgopoulos A, Rendell M, etal. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981 4 579-585
14. van Cauter E, Desir D, Decoster C, etal. Nocturnal decrease in glucose tolerance during constant glucose infusion. J Clin Endocrinol Metab 1989 69 604-611